NDAINHALATIONGAS
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
OXYGEN, USP (oxygen) by Advanced Solutions Life Sciences. Approved for chronic obstructive pulmonary disease, hypoxia, acute respiratory distress syndrome and 2 more indications. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXYGEN, USP is a gaseous therapeutic agent administered via inhalation for the treatment of hypoxemia and respiratory failure across multiple acute and chronic conditions. It is indicated for COPD, hypoxia, ARDS, acute respiratory failure, and COVID-19. Oxygen functions as a basic physiologic necessity rather than a traditional pharmacologic agent, restoring adequate tissue oxygenation in patients with compromised respiratory function.
Peak
As a commodity respiratory therapeutic at peak lifecycle with low competitive pressure (30), this product likely operates in a stable, mature market with smaller commercial teams focused on distribution and reimbursement management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (5)
Worked on OXYGEN, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.